Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12.0 months (95% CI: 10.7-15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5-13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357-0.829; p=0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354-0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study / Gardini, Andrea Casadei; Foca, Flavia; Scartozzi, Mario; Silvestris, Nicola; Tamburini, Emiliano; Faloppi, Luca; Brunetti, Oronzo; Rudnas, Britt; Pisconti, Salvatore; Valgiusti, Martina; Marisi, Giorgia; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Tassinari, Davide; Cascinu, Stefano; Frassineti, Giovanni Luca. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 7:(2017), pp. 1-7. [10.1038/srep42499]

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study

Gardini, Andrea Casadei
;
Scartozzi, Mario;Cascinu, Stefano;
2017

Abstract

Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line treatment. This multicentric study retrospectively analyzed data of HCC patients unresponsive or intolerant to sorafenib treatment with metronomic capecitabine or best supportive care (BSC).Median progression free survival was 3.1 months in patients treated with capecitabine (95%CI: 2.7-3.5). Median overall survival was 12.0 months (95% CI: 10.7-15.8) in patients receiving capecitabine, while 9.0 months (95% CI: 6.5-13.9) in patients receiving BSC. The result of univariate unweighted Cox regression model shows a 46% reduction in death risk for patients on capecitabine (95%CI: 0.357-0.829; p=0.005) compared to patients receiving BSC alone. After weighting for potential confounders, death risk remained essentially unaltered (45%; 95%CI: 0.354-0.883; p = 0.013). Metronomic capecitabine seems a safe second-line treatment for HCC patients in terms of management of adverse events, showing a potential anti-tumour activity which needs further evaluation in phase III studies.
7
1
7
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study / Gardini, Andrea Casadei; Foca, Flavia; Scartozzi, Mario; Silvestris, Nicola; Tamburini, Emiliano; Faloppi, Luca; Brunetti, Oronzo; Rudnas, Britt; Pisconti, Salvatore; Valgiusti, Martina; Marisi, Giorgia; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Tassinari, Davide; Cascinu, Stefano; Frassineti, Giovanni Luca. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 7:(2017), pp. 1-7. [10.1038/srep42499]
Gardini, Andrea Casadei; Foca, Flavia; Scartozzi, Mario; Silvestris, Nicola; Tamburini, Emiliano; Faloppi, Luca; Brunetti, Oronzo; Rudnas, Britt; Pisconti, Salvatore; Valgiusti, Martina; Marisi, Giorgia; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Tassinari, Davide; Cascinu, Stefano; Frassineti, Giovanni Luca
File in questo prodotto:
File Dimensione Formato  
Metronomic capecitabine versus best supportive care as second- line treatment in hepatocellular carcinoma- a retrospective study.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 372.03 kB
Formato Adobe PDF
372.03 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177502
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 28
social impact